Eli Lilly (LLY) news
Recent news
Trex Bio indicated at $14.50; IPO price $14
Trex Bio has set an initial public offering (IPO) price of $14 per share, slightly below its indicated price of $14.50, according to recent filings. The clinical-stage biopharmaceutical company is seeking to raise capital to advance its pipeline of therapies targeting autoimmune and inflammatory…
AInvest Wire · 3d agoQuotation resumed: (TRXB) IPO security released for quotation
TRex Bio Inc. (TRXB) has resumed quotation for its upcoming initial public offering (IPO), following the announcement of its proposed $125 million offering. The biotechnology firm, supported by Eli Lilly & Co., plans to issue 8.33 million shares at a price range of $14.00 to $16.00 per share, with…
AInvest Wire · 3d agoTrex Bio said to allocate 80% of IPO shares to 10 investors
Trex Bio has reportedly allocated 80% of its initial public offering (IPO) shares to a group of 10 institutional investors, according to recent reports. This allocation suggests a strategic approach to securing strong pre-IPO commitments, which could help stabilize the offering and provide early…
AInvest Wire · 3d agoEli Lilly: Improvements were maintained or further improved through week 52, with safety consistent with known profile of each respective medicine
Eli Lilly and Company recently reported that improvements observed in clinical trials for its respective medicines were maintained or further improved through week 52 of evaluation. The company noted that the safety profile of each medicine remained consistent with previously established data,…
AInvest Wire · 3d agoEli Lilly - Taltz and Zepbound together show broader biomarker changes vs. Taltz alone
Recent clinical findings suggest that the combination of Eli Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) may lead to broader biomarker changes compared to Taltz alone, according to preliminary data. Taltz, a biologic medication targeting the inflammatory protein IL-17A, is used to treat…
AInvest Wire · 3d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.